| Autor: |
Gozalishvilli-Boncheva A; Registro de Cáncer de Baja California Sur, La Paz. B.C.S, México., Gonzalez-Espinoza IR; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Castro-Ponce A; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Bravo-Gutiérrez OA; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Juárez-Salazar G; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Montes-de-Oca-Moreda RI; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Aguirre-Flores E; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Coyotl-Huexotl M; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Orozco-Luis J; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Chiquillo-Domínguez M; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Garibay-Díaz JC; Hospital MAC, Tlaxcalancingo, Puebla, México., Aranda-Claussen JE; Hospital Betania, Puebla, Puebla, México., Ponce-de-León EA; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Sánchez-Sosa S; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Sabaté-Fernández M; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., García-Reyna JC; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Cordero-Vargas C; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., González-Blanco MJ; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Aguilar-Priego JM; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Sánchez-Fernández NJ; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Cortés-García CA; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., González-Lozada LE; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Miguel-Cruz E; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Ceja-Utrera FJ; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México., Hernández-Garcia MS; Registro de Cáncer de Baja California Sur, La Paz. B.C.S, México., Piña-Vazquez M; Registro de Cáncer de Baja California Sur, La Paz. B.C.S, México., Aguilar-Jiménez C; Centro oncológico integral Hospital Ángeles Puebla, Puebla, México. |
| Abstrakt: |
Breast cancer is the most incidental and deadly neoplasm worldwide; in Mexico, very few epidemiologic reports have analyzed the pathological features and its impact on their clinical outcome. Here, we studied the relation between pathological features and the clinical presentation at diagnosis and their impact on the overall and progression-free survival of patients with breast cancer. For this purpose, we collected 199 clinical records of female patients, aged at least 18 years old (y/o), with breast cancer diagnosis confirmed by biopsy. We excluded patients with incomplete or conflicting clinical records. Afterward, we performed an analysis of overall and progression-free survival and associated risks. Our results showed an average age at diagnosis of 52 y/o (24-85), the most common features were: upper outer quadrant tumor (32%), invasive ductal carcinoma (76.8%), moderately differentiated (44.3%), early clinical stages (40.8%), asymptomatic patients (47.8%), luminal A subtype (47.8%). Median overall survival was not reached, but median progression-free survival was 32.2 months (29.75-34.64, CI 95%) associated risk were: clinical stage (p < 0.0001) symptomatic presentation (p = 0.009) and histologic grade (p = 0.02). Therefore, we concluded that symptom presence at diagnosis impacts progression-free survival, and palpable symptoms are related to an increased risk for mortality. |
